Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
Background: Left atrial appendage closure (LAAC) with Watchman device is an alternative strategy to oral anticoagulation for decreasing ischemic stroke risk in selected patients with non –valvular ...
Left atrial appendage occlusion (LAAO) with the WATCHMAN FLX (Boston Scientific) has been proven to reduce stroke risk in patients with paroxysmal atrial fibrillation (PAF). Certain circumstances may ...
We remain bullish on the Watchman left atrial appendage closure franchise (despite Abbott's competitive presence) and increased adoption of the S-ICD and advances in spinal cord stimulation for ...
This trial evaluates the potential market expansion for Boston Scientific's left-atrial-appendage-closure (LAAC) device, WATCHMAN. Furthermore, Boston Scientific's acquisition of Silk Road Medical ...
The OPTION trial is a significant study for Boston Scientific as it evaluates the potential market expansion for its left-atrial-appendage-closure (LAAC) device, WATCHMAN, which is projected to ...
This trial evaluates the potential market expansion for Boston Scientific's left-atrial-appendage-closure (LAAC) device, WATCHMAN. Furthermore, Boston Scientific's acquisition of Silk Road Medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback